Charles River Laboratories International (NYSE: CRL) and Pluristem Therapeutics (NASDAQ:PSTI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Insider and Institutional Ownership
95.4% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 4.5% of Pluristem Therapeutics shares are owned by institutional investors. 2.2% of Charles River Laboratories International shares are owned by insiders. Comparatively, 7.0% of Pluristem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Charles River Laboratories International and Pluristem Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories International||10.13%||27.02%||8.84%|
Volatility & Risk
Charles River Laboratories International has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.
This is a summary of recent recommendations for Charles River Laboratories International and Pluristem Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories International||0||5||4||0||2.44|
Charles River Laboratories International currently has a consensus target price of $101.28, suggesting a potential downside of 10.31%. Pluristem Therapeutics has a consensus target price of $4.13, suggesting a potential upside of 141.23%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Pluristem Therapeutics is more favorable than Charles River Laboratories International.
Valuation and Earnings
This table compares Charles River Laboratories International and Pluristem Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Charles River Laboratories International||$1.81 billion||2.97||$435.89 million||$3.81||29.64|
|Pluristem Therapeutics||N/A||N/A||-$25.84 million||($0.32)||-5.34|
Charles River Laboratories International has higher revenue and earnings than Pluristem Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
Charles River Laboratories International beats Pluristem Therapeutics on 8 of the 11 factors compared between the two stocks.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.
Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.